Overview

SADBE for Congenital Melanocytic Nevi

Status:
Not yet recruiting

Trial end date:
2028-01-01

Target enrollment:

Participant gender:

Summary

A study to evaluate the safety and efficacy topical squaric acid dibutylester (SADBE) for the neoadjuvant treatment of congenital melanocytic nevi (CMN).

Phase:

Early Phase 1

Details

Lead Sponsor:

Massachusetts General Hospital

Treatments:

Ethanol
Squaric acid dibutyl ester